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Abstract
Background: Healthy people with a family history of alcohol problems show a pattern of subjective responses to alcohol that 
resemble those of affected probands. Studies on ketamine suggest that up-regulation of N-methyl-D-aspartate receptors 
(NMDARs) underlies these effects, and point to a pharmacologically-responsive endophenotype reflecting enhanced risk for 
alcohol-use disorders.
Methods: Subjective stimulant and sedative effects were assessed before and during nitrous oxide (N2O; 50%) inhalation in 
heavy drinkers who were otherwise healthy.
Results: Participants with an ostensible family history of alcohol-use disorders (n  =  23) were distinguishable from those 
without such familial risk (n = 37) by an enhanced stimulation-to-sedation ratio during N2O inhalation.
Conclusion: The pattern of subjective effects of N2O according to familial risk is remarkably similar to that previously seen 
with ketamine, supporting the idea of a common, NMDAR-mediated mechanism of action. N2O may prove to be a safe and 
accessible alternative to ketamine for probing heritable NMDAR dysregulation in neuropsychiatric disorders.
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Introduction
Individuals with a positive family history (FH+) of alcohol use 
disorder (AUD) are themselves at elevated risk of developing 
AUD (Hesselbrock and Hesselbrock, 1992). These individuals also 
have a tendency to experience greater reinforcing and stimu-
lant effects, relative to dysphoric and sedating effects, of alcohol 
(Morean and Corbin, 2010). Given the complex pharmacology of 
alcohol, delineation of the underlying neurobiology of this mixed 
pattern of subjective responses may seem especially challenging. 
However, since N-methyl-D-aspartate receptors (NMDARs) are 
key regulators of the reinforcing and intoxicating effects of alco-
hol, and are functionally up-regulated following chronic ethanol 
treatment in animal studies (Wang et al., 2007; see Krystal et al, 
2003a), one possibility is that this stimulant effect bias reflects 
altered NMDARs functioning within central reward pathways 
(Vengeliene et al., 2008). Support for this notion is found in stud-
ies examining the effects of ketamine, a high-affinity NMDAR 
antagonist, in those with historic and/or familial risk of AUD. For 
example, recently detoxified AUD patients exhibit blunted posi-
tive and negative psychosis-like responses, as well as insensitiv-
ity to the dysphoric effects of ketamine (Krystal et al., 2003b).
A similar mixed pattern of subjective effects has been found 
in response to ketamine in healthy, non-dependent FH+ drinkers 
(Krystal et al., 2003a; Petrakis et al., 2004; Yoon et al., 2016). Low-
affinity NMDAR antagonists also produce distinct subjective, 
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behavioral, and neural responses in healthy individuals accord-
ing to family history of AUD (Jamadar et  al., 2012; Narayanan 
et  al., 2013). These findings suggest that the alterations in 
NMDAR function underlying the distinct subjective responses 
to antagonists cannot be attributed to chronic exposure to high 
doses of ethanol alone (as in AUD patients; Krystal et al., 2003b).
Like ketamine, nitrous oxide (N2O) is a dissociative anaes-
thetic and primarily an antagonist at the NMDAR (Jevtović-
Todorović et  al., 1998). Its therapeutic potential, based on 
NMDAR antagonism, has only recently been explored in relation 
to psychiatric disorders (Nagele et al., 2015; Das et al., 2016). In 
the current study we draw on recent work showing an increase 
in the subjective stimulant-to-sedative ratio following keta-
mine administration in people with an inherited vulnerability 
to AUD (Yoon et  al., 2016). We examined whether subjective 
responses to N2O—potentially also reflecting heritable NMDAR 
dysregulation, as above—differed in FH+ individuals compared 
to those without such histories (FH-). Such a pattern might sug-
gest a common neuropsychopharmacological substrate for the 
subjective effects of N2O and ketamine. Moreover, similarities 
to ketamine would support the use of N2O as a convenient and 
safe pharmacodiagnostic/therapeutic agent for interrogating/
treating NMDAR dysregulation in neuropsychiatric disorders. 
This would be an important development given that the phar-
macopoeia of NMDAR-ergic agents is currently very small, its 
use limited (at least in the case of ketamine) by the potential for 
acute psychotomimetic and dysphoric effects, and the need for 
careful monitoring of such effects. N2O produces similar effects, 
though they are milder and reverse within minutes of terminat-
ing inhalation.
Material and Methods
The study was approved by University College London Research 
Ethics Committee. All participants provided written, informed 
consent and all procedures were carried out in accordance 
with the Declaration of Helsinki code of ethics for experiments 
involving human subjects. The data described here are part of a 
larger dataset from a study on the effects of N2O on reconsoli-
dation of alcohol-related memories. Participants attended three 
sessions separated by at least 48 hs. The data presented here 
is primarily from session 2, the only session during which any 
drug (N2O) was administered.
Procedure
Prior to attendance, participants underwent a screening inter-
view to establish eligibility. They also completed standardized 
alcohol-related assessments (e.g. measures of alcohol con-
sumption and craving) and assessment of family history prior 
to attending session 2. After taking a breathalyzer test (Lion 500 
portable Alcometer; Lion Instruments) at the beginning of ses-
sion 2 (all gave a reading of 0.00), participants completed base-
line subjective state measures, inhaled N2O for 10 min, and then 
repeated the subjective state assessments while continuing to 
inhale N2O.
Participants
Eligibility criteria included: an absence of current psychiatric 
disorder; no use of psychotropic medication; no history of drug 
and alcohol dependence (as assessed using the alcohol module 
of the Structured Clinical Interview for DSM IV); an absence of 
any medical contraindications to use of N2O; aged 18–50 years; 
scoring >8 on the Alcohol Use Disorders Identification Test 
(AUDIT; Babor et al., 2001); and regularly drinking more alcohol 
than the UK government recommended maximum (112 and 
168 g/week for women and men, respectively). As such, partici-
pants were at risk of developing AUD on the basis of current 
drinking patterns and AUDIT scores. This risk of transitioning 
from heavy to disordered alcohol use is underscored by partici-
pants’ mean age (Table 1), which is within the range of greatest 
relevance for such transition (King et al., 2015). Sixty individu-
als met criteria and attended experimental sessions. They were 
classified as either FH+ (n = 23) or FH- (n = 37; see below).
Baseline Alcohol-Related Assessments
Baseline group differences were examined across a variety of 
alcohol-related measures. Alcohol consumption was assessed 
using the one week Timeline Followback (TLFB) procedure (Sobell 
and Sobell, 1992). An infographic was provided to orient partici-
pants to alcohol quantities in typical drinks (in terms of UK units), 
which are expressed as grams of pure alcohol in this report.
Tonic craving at baseline was assessed using the 12-item 
Alcohol Craving Questionnaire-Now (ACQ-Now; Singleton et al., 
1994), and cue-elicited drinking urge and stimulus pleasantness, 
using an alcohol picture rating task. Pleasantness and urge rat-
ings were on a 0 = “extremely unpleasant/greatly decreases” to 
10 = “extremely pleasant/greatly increases” scale.
Given that exploration of heritability was a secondary aim 
in this study, a brief assessment of family history was deemed 
to be more suitable than a full familial-diagnostic interview. As 
such, participants were asked to indicate which, if any, relatives 
within the family tree of first- and second-degree maternal and 
paternal family members in the current and previous two gen-
erations had experienced alcohol-related problems (Mann et al., 
1985). Importantly, such brief assessment methods perform 
nearly as well as full-scale measures of family history, with high 
levels of agreement between family members (Prescott et  al., 
2005). Participants were classified as FH+ if they identified either 
(or both) biological parent(s), or FH- otherwise.
Mood and Anxiety
The Hospital Anxiety and Depression Scale was used to gauge 
levels of depressed mood and anxiety (Zigmond and Snaith, 
1983).
Table 1. Demographic and Alcohol-Related Variables for Participants 
Without (FH-) and With (FH+) a Family History of Alcohol Problems.
FH- FH+
Women: n(%)  16 (43%)  7 (30%)
Age (years)  25.95 (8.14)  26.78 (9.00)
AUDIT score  13.68 (3.49)  16.35 (5.80)
Alcohol (g/week) 315.55 (149.55) 298.63 (103.53)
Tonic craving (ACQ-Now)  32.14 (8.65)  34.11 (6.81)
Picture rating (alcohol liking)  6.60 (1.07)  6.33 (1.21)
Picture rating (alcohol urge)  5.76 (1.14)  5.73 (1.26)
Depression (HADS)  2.51 (2.47)  3.04 (3.23)
Anxiety (HADS)  6.57 (3.72)  5.83 (3.34)
Except for number (proportion) of women, values are means (± 
standard deviations). ACQ-Now, Alcohol Craving Questionnaire-Now; 
AUDIT, Alcohol Use Disorders Identification Test; HADS, Hospital 
Anxiety and Depression Scale.
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Subjective Response to Nitrous Oxide
A 12-item visual analogue Bodily Symptoms Scale (BSS; 
recorded on a 0–100 scale), reflecting expected N2O effects, 
and the participant-rated items of the Clinician Administered 
Dissociative States Scale (CADSS; Bremner et  al., 1998) were 
used to assess subjective states immediately before (base-
line) and after 10 mins of N2O inhalation. Our interest related 
to responses to the euphoria and drowsiness items, which, 
following Yoon and colleagues, were expressed as a single 
stimulant-to-sedative ratio (Yoon et al., 2016) at baseline and 
during-N2O inhalation.
Nitrous Oxide Administration
We administered 50% N2O in oxygen (Entonox, British Oxygen 
Company) via an Ultraflow demand valve regulator (BPR 
Medical Ltd) for a total of 30 min. Participants remained in 
the department for 30 min after the end of the experiment 
to ensure N2O effects had completely worn off and they 
were well-oriented to time and place before leaving the 
department.
Statistical Analysis
Data was analyzed using SPSS version 22 (IBM) and, unless 
indicated, is presented as mean ± standard error of the mean 
throughout. Variables were examined for normality of distribu-
tions. Negatively skewed (stimulation-to-sedation ratio) data 
were +1 log transformed prior to a mixed factorial 2 (time as 
baseline; during N2O) x 2 (group as FH
+ or FH-).
For ease of interpretation, raw (untransformed) values 
(which produced the same statistical outcome as transformed 
values) are shown in Figure  1. These between-/within-subject 
factors were also used in the analysis of CADSS data. Significant 
interactions were explored using Bonferroni corrected pair-wise 
post hoc tests. Independent sample t-tests were used to com-
pare the groups’ baseline characteristics. Where the assumption 
of equality of variance was violated for independent sample 
t-tests, statistical correction was applied, and t-values and dfs 
adjusted accordingly. A small amount of missing data (~6%) is 
reflected in lower degrees of freedom in the reported analysis 
than expected for the sample size.
Results
FH+ and FH- groups had similar mean ages and gender composi-
tion. There were no significant differences between FH+ and FH- 
groups on any alcohol- or affect-related variables (χ- or t-values 
≤ 2; p-values >0.05; Table 1).
There was a significant three-way interaction between time 
(pre- or during N2O), family history (FH
+, FH-), and scale [stim-
ulation, sedation; F(1,54) = 6.98, p = 0.011, • p
2 = 0.115]. Pairwise, 
Bonferonni corrected post hoc tests comparing pre- and during 
N2O stimulation levels showed that FH
- participants did not expe-
rience a significant increase in stimulation (mean change ± SEM: 
+7.35 ± 6.01; p > 0.1), whereas FH+ participants did (+20.23 ± 7.47; 
p  =  0.009). Similarly, while there was a small non-significant 
increase in sedation among FH- individuals (+5.68 ± 5.33; p > 0.1), 
a relatively large decrease in sedation from pre- to during N2O 
(-16.36 ± 6.23; p = 0.017) was found in FH+ participants.
To allow a more direct comparison with the pattern of effects 
described with ketamine (Yoon et  al., 2016), the simultaneous 
effects of N2O on stimulation and sedation were also expressed 
and analyzed as a stimulant-to-sedative ratio. As expected, 
a significant Time x Group interaction [F(1,54) = 7.91, p  < 0.01, 
ηp2 = 0.128] was found on these ratio scores (Figure 1), with post 
hoc tests showing that an increase in stimulation-to-sedation 
from baseline to during N2O was only observed in FH
+ partici-
pants (p < 0.01).
In contrast, CADSS scores showed only a main effect of Time, 
reflecting similar increases from baseline to during N2O in the 
FH- (+15.53 ± 2.02) and FH+ [+14.39 ± 2.53; F(1,57) = 85.63, p < 0.01].
Discussion
In this study we examined whether healthy individuals with-
out alcohol dependence, but with a positive family history 
of alcohol problems, showed a similar pattern of subjective 
responses following N2O to those reported in other stud-
ies following ketamine administration (Krystal et al., 2003a; 
Petrakis et al., 2004; Yoon et al., 2016). In fact, the pattern we 
observed on the stimulant-to-sedative ratio measure was 
strikingly similar to the Group (FH+/FH-) by Time (pre-/during 
drug) interaction observed with ketamine (Yoon et al., 2016). 
It is possible that the overlapping in vitro neuropharmacology 
of N2O and ketamine (Jevtović-Todorović et al., 2001) under-
lies this similarity. More specifically, this common pattern 
of subjective responses in FH+ individuals is consistent with 
the notion that altered responses to dissociative-anaesthetic 
NMDAR antagonists are a potential pharmaco-endopheno-
type reflecting intergenerational transmission of dysregu-
lated NMDAR function underlying AUDs. A full determination 
of the endophenotype-status of such responses requires 
further research, although, as with alcohol, the subjective 
response to N2O possesses at least some of the character-
istics expected of an endophenotype (Morean and Corbin, 
2010). Alternatively (or in addition), N2O response in FH
 + par-
ticipant may reflect epigenetic influences or chronic neural 
dysregulation resulting from developmental adversity (aris-
ing from one or both parents’ excessive drinking). Previous 
research has partially addressed this concern by not includ-
ing FH+ participants with alcohol-dependent mothers, thus at 
least reducing the possibility that pre-natal exposure to toxic 
alcohol effects contributed to differential responses in FH+ 
participants (e.g. Petrakis et al., 2004).
While we cannot rule out the possibility that the observed 
effects of N2O reflect its action on neurotransmitter systems other 
than NMDARs, the established receptor-level pharmacological 
Figure 1. Ratio of stimulant to sedative effects of nitrous oxide (N2O) inhalation 
in participants without (FH-) and with (FH+) a family history of alcohol problems 
at baseline and during N2O inhalation. Bars represent (untransformed) esti-
mated marginal means and associated standard errors of the means.
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similarities and the convergence of findings from human psy-
chopharmacological studies across various NMDAR antagonists 
makes an NMDAR-mediated account of the current findings the 
most parsimonious. If our findings do reflect the action of N2O 
on a heritable dysregulated NMDAR system, they suggest that 
research participants are reliably able to identify this dysregula-
tion through its ultimate expression: namely, in the behavior of 
their relatives. In addition, the results potentially indicate that 
expression of NMDAR dysfunction in FH+ individuals is associ-
ated with a lower threshold of problem severity (among rela-
tives) than has been implied by previous studies with ketamine, 
in which FH+ participants were those with alcohol-dependent 
family members (Petrakis et al., 2004; Yoon et al., 2016).
Our findings have potentially important clinical implications. 
For example, an appraisal of family history of alcohol problems 
may be important when determining the suitability of N2O (or 
other NMDAR antagonists) as a treatment for depression (Phelps 
et al., 2009; Nagele et al., 2015), post-traumatic stress disorder 
(Das et al., 2016), and addictions (David et al., 2006). Given the 
recent surge of interest in NMDAR antagonists as novel pharma-
cotherapeutics for major depressive disorder (Coyle and Laws, 
2015; Nagele et al., 2015), an improved understanding of predic-
tors of NMDAR antagonist responses will be key for understand-
ing variability in treatment and may facilitate the development 
of personalized interventions for depression. Despite these pos-
sibilities, it is important to extend our preliminary findings. For 
example, a future study should use standardized assessments 
of subjective drug effects, and assess the similarity of N2O’s 
effects to those of alcohol (e.g. using the biphasic alcohol effects 
scale; Yoon et al, 2016).
In sum, the subjective response to N2O may be an efficient 
and convenient pharmacological probe that signals NMDAR 
dysfunction and in turn, increased risk of neuropsychiatric 
disorders or probable treatment response. While evidence 
mounts that ketamine is a valuable and potent probe drug 
and pharmacotherapeutic agent, there continues to be a 
need for effective, easily-administered, and rapidly-reversing 
NMDAR antagonists for use in the prognostics and treatment 
of neuropsychiatric disorders. N2O appears to have these 
properties.
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